3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Cholangiocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Papillomavirus Infections
1
Oncogenic osteomalacia
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Hypophosphatemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Acrocephalosyndactylia
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
infigratinib
×
Clear all
NCT02160041
2019-06-18
CBGJ398XUS04
Novartis
Phase 2
Terminated
84 enrolled
15 charts